Table 1

Risk of leukaemia, lymphoma and brain cancer, stratified analysis

nO/ESIR (95% CI)
All83 935168/901.9 (1.6 to 2.2)
 Boys47 65089/531.7 (1.3 to 2.1)
 Girls36 28579/372.2 (1.7 to 2.7)
Age
 0–470 476135/761.8 (1.5 to 2.1)
 5–9814514/81.7 (0.9 to 2.8)
 10–1431148/32.3 (1.0 to 4.5)
 15–17220011/34.2 (2.1 to 7.5)
Previous hospitalisations
 018 11420/171.2 (0.7 to 1.9)
 145 16194/501.9 (1.5 to 2.3)
 211 95324/141.8 (1.1 to 2.6)
 3+870730/103.1 (2.1 to 4.4)
Calendar period
 1994–199821 61896/811.2 (1.0 to 1.4)
 1999–200321 06761/491.3 (1.0 to 1.6)
 2004–200820 64454/291.9 (1.4 to 2.5)
 2009–201320 60730/122.5 (1.7 to 3.5)
Congenital malformations
 Yes873331*/93.7 (2.5 to 5.2)
 Down syndrome4899/116.2 (7.4 to 30.8)
 No75 202137/811.7 (1.4 to 2.0)
Immune deficiency
 Yes1372/0.117.5 (2.1 to 63.2)
 No83 798166/901.9 (1.6 to 2.2)
Imaging examination (after 2002)
 Yes36 23066/252.7 (2.1 to 3.4)
 No13 2809/81.1 (0.5 to 2.1)
  • Congenital malformations included conditions related to the nervous system (Q00-Q07); eye, ear, face and neck (Q10-Q18); the circulatory system (Q20-Q28); the respiratory system (Q30-Q34); cleft lip and cleft palate (Q35-Q37); the digestive system (Q38-Q45); genital organs (Q50-Q56); the urinary system (Q60-Q64); malformations and deformations of the musculoskeletal system (Q65-Q79) and other (Q80-Q99).

  • O/E, observed/expected number of cancer; SIR, standardised incidence ratio.